Free Standard AU & NZ Shipping For All Book Orders Over $80!
Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
EDITORIAL

Gonorrhoea: tackling the global epidemic in the era of rising antimicrobial resistance

Jason J. Ong A B G , Teodora Wi C , Gwenda Hughes https://orcid.org/0000-0003-2090-7702 D , Deborah A. Williamson E , Philippe Mayaud B and Eric P. F. Chow https://orcid.org/0000-0003-1766-0657 A F
+ Author Affiliations
- Author Affiliations

A Central Clinical School, Monash University, Melbourne, Vic. 3053, Australia.

B Department of Clinical Research, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

C Department of Reproductive Health and Research, World Health Organization, Geneva 1211, Switzerland.

D National Infection Service, Public Health England, Colindale NW9 5EQ, UK.

E Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology & Immunology, The University of Melbourne at The Doherty Institute for Infection and Immunity, Melbourne, Vic. 3000, Australia.

F Melbourne Sexual Health Centre, Alfred Health, Carlton, Vic. 3053, Australia.

G Corresponding author. Email: jong@mshc.org.au

Sexual Health 16(5) 397-400 https://doi.org/10.1071/SH19121
Submitted: 9 July 2019  Accepted: 15 July 2019   Published: 13 September 2019

Abstract

This Special Issue of Sexual Health aims to collate the latest evidence base focussed on understanding the current epidemic and transmission of gonorrhoea, choice of treatment, molecular epidemiology application, concerns about antimicrobial resistance and alternative prevention and control for gonorrhoea.


References

[1]  World Health Organization (WHO). Report on global sexually transmitted infection surveillance, 2018. Geneva: WHO; 2018. Available online at: https://www.who.int/reproductivehealth/publications/stis-surveillance-2018/en/ [verified 8 August 2019].

[2]  Chow EPF, Grulich AE, Fairley CK. Epidemiology and prevention of sexually transmitted infections in men who have sex with men at risk of HIV. Lancet HIV 2019; 6 e396–405.
Epidemiology and prevention of sexually transmitted infections in men who have sex with men at risk of HIV.Crossref | GoogleScholarGoogle Scholar | 31006612PubMed |

[3]  Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, et al Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med 2017; 14 e1002344
Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action.Crossref | GoogleScholarGoogle Scholar | 28746372PubMed |

[4]  Eyre DW, Sanderson ND, Lord E, Regisford-Reimmer N, Chau K, Barker L, et al Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill 2018; 23 pii=1800323
Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018.Crossref | GoogleScholarGoogle Scholar | 29991383PubMed |

[5]  Ndowa F, Lusti-Narasimhan M. The threat of untreatable gonorrhoea: implications and consequences for reproductive and sexual morbidity. Reprod Health Matters 2012; 20 76–82.
The threat of untreatable gonorrhoea: implications and consequences for reproductive and sexual morbidity.Crossref | GoogleScholarGoogle Scholar | 23245412PubMed |

[6]  Hayes R, Watson-Jones D, Celum C, van de Wijgert J, Wasserheit J. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS 2010; 24 S15–26.
Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?Crossref | GoogleScholarGoogle Scholar | 21042049PubMed |

[7]  Kirkcaldy RD, Weston E, Segurado AC, Hughes G. Epidemiology of gonorrhoea: a global perspective. Sex Health 2019; 16 401–411.
Epidemiology of gonorrhoea: a global perspective.Crossref | GoogleScholarGoogle Scholar |

[8]  Unemo M, Lahra MM, Cole M, Galarza P, Ndowa F, Martin I, et al World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts. Sex Health 2019; 16 412–425.
World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts.Crossref | GoogleScholarGoogle Scholar |

[9]  Callander D, Guy R, Fairley CK, McManus H, Prestage G, Chow EPF, et al Gonorrhoea gone wild: rising incidence of gonorrhoea and associated risk factors among gay and bisexual men attending Australian sexual health clinics. Sex Health 2019; 16 457–463.
Gonorrhoea gone wild: rising incidence of gonorrhoea and associated risk factors among gay and bisexual men attending Australian sexual health clinics.Crossref | GoogleScholarGoogle Scholar |

[10]  Kohli M, Hickson F, Free C, Reid D, Weatherburn P. Cross-sectional analysis of chemsex drug use and gonorrhoea diagnosis among men who have sex with men in the UK. Sex Health 2019; 16 464–472.
Cross-sectional analysis of chemsex drug use and gonorrhoea diagnosis among men who have sex with men in the UK.Crossref | GoogleScholarGoogle Scholar |

[11]  Phillips TR, Fairley CK, Chen MY, Bradshaw CS, Chow EPF. Risk factors for urethral gonorrhoea infection among heterosexual males in Melbourne, Australia: 2007–17. Sex Health 2019; 16 508–513.
Risk factors for urethral gonorrhoea infection among heterosexual males in Melbourne, Australia: 2007–17.Crossref | GoogleScholarGoogle Scholar |

[12]  Loo LS, Cisera K, Korman TM, Woolley I. Management of gonorrhoea in a hospital network: are we following best practice? Sex Health 2019; 16 523–525.
Management of gonorrhoea in a hospital network: are we following best practice?Crossref | GoogleScholarGoogle Scholar |

[13]  Fairley CK, Zhang L, Chow EPF. New thinking on gonorrhoea control in MSM: are antiseptic mouthwashes the answer? Curr Opin Infect Dis 2018; 31 45–49.
New thinking on gonorrhoea control in MSM: are antiseptic mouthwashes the answer?Crossref | GoogleScholarGoogle Scholar | 29176445PubMed |

[14]  Gottlieb SL, Jerse AE, Delany-Moretlwe S, Deal C, Giersing BK. Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap. Sex Health 2019; 16 426–432.
Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap.Crossref | GoogleScholarGoogle Scholar |

[15]  Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, et al Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet 2017; 390 1603–10.
Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study.Crossref | GoogleScholarGoogle Scholar | 28705462PubMed |

[16]  Fairley CK, Hocking JS, Zhang L, Chow EP. Frequent transmission of gonorrhea in men who have sex with men. Emerg Infect Dis 2017; 23 102–4.
Frequent transmission of gonorrhea in men who have sex with men.Crossref | GoogleScholarGoogle Scholar | 27983487PubMed |

[17]  Chow EP, Howden BP, Walker S, Lee D, Bradshaw CS, Chen MY, et al Antiseptic mouthwash against pharyngeal Neisseria gonorrhoeae: a randomised controlled trial and an in vitro study. Sex Transm Infect 2017; 93 88–93.
Antiseptic mouthwash against pharyngeal Neisseria gonorrhoeae: a randomised controlled trial and an in vitro study.Crossref | GoogleScholarGoogle Scholar | 27998950PubMed |

[18]  Chow EPF, Walker S, Hocking JS, Bradshaw CS, Chen MY, Tabrizi SN, et al A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study protocol. BMC Infect Dis 2017; 17 456
A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study protocol.Crossref | GoogleScholarGoogle Scholar | 28659133PubMed |

[19]  Phillips T, Fairley CK, Walker S, Chow EPF. Associations between oral sex practices and frequent mouthwash use in men who have sex with men: implications for gonorrhoea prevention. Sex Health 2019; 16 473–478.
Associations between oral sex practices and frequent mouthwash use in men who have sex with men: implications for gonorrhoea prevention.Crossref | GoogleScholarGoogle Scholar |

[20]  Chow EPF, Maddaford K, Trumpour S, Fairley CK. Translating mouthwash use for gonorrhoea prevention into a public health campaign: identifying current knowledge and research gaps. Sex Health 2019; 16 433–441.
Translating mouthwash use for gonorrhoea prevention into a public health campaign: identifying current knowledge and research gaps.Crossref | GoogleScholarGoogle Scholar |

[21]  Hall CL, Harrison MA, Pond MJ, Chow C, Harding-Esch EM, Sadiq ST. Genotypic determinants of fluoroquinolone and macrolide resistance in Neisseria gonorrhoeae. Sex Health 2019; 16 479–487.
Genotypic determinants of fluoroquinolone and macrolide resistance in Neisseria gonorrhoeae.Crossref | GoogleScholarGoogle Scholar |

[22]  Deng X, Allan-Blitz LT, Klausner JD. Using the genetic characteristics of Neisseria gonorrhoeae strains with decreased susceptibility to cefixime to develop a molecular assay to predict cefixime susceptibility. Sex Health 2019; 16 488–499.
Using the genetic characteristics of Neisseria gonorrhoeae strains with decreased susceptibility to cefixime to develop a molecular assay to predict cefixime susceptibility.Crossref | GoogleScholarGoogle Scholar |

[23]  Mensforth S, Ross JDC. Should we still use azithromycin for gonorrhoea treatment? Sex Health 2019; 16 442–448.
Should we still use azithromycin for gonorrhoea treatment?Crossref | GoogleScholarGoogle Scholar |

[24]  Lewis DA. New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance. Sex Health 2019; 16 449–456.
New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance.Crossref | GoogleScholarGoogle Scholar |

[25]  Zienkiewicz AK, Verschueren van Rees N, Homer M, Ong JJ, Christensen H, Hill D, et al Agent-based modelling study of antimicrobial resistant Neisseria gonorrhoeae transmission in men who have sex with men: towards individualised diagnosis and treatment. Sex Health 2019; 16 514–522.
Agent-based modelling study of antimicrobial resistant Neisseria gonorrhoeae transmission in men who have sex with men: towards individualised diagnosis and treatment.Crossref | GoogleScholarGoogle Scholar |

[26]  Ebeyan S, Windsor M, Bordin A, Mhango L, Erskine S, Trembizki E, et al Evaluation of the ResistancePlus GC (beta) assay: a commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae. J Antimicrob Chemother 2019; 74 1820–24.
Evaluation of the ResistancePlus GC (beta) assay: a commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae.Crossref | GoogleScholarGoogle Scholar | 30897201PubMed |